Ascites Market is expected to grow by 2032, estimates DelveInsight
DelveInsight’s Ascites Market Insights report includes a comprehensive understanding of current treatment practices, ascites emerging drugs, market share of individual therapies, and current and forecasted ascites market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Ascites Market Report
- According to DelveInsight’s analysis, the market size for ascites across the 7MM is expected to grow with a significant CAGR by 2032.
- DelveInsight’s analysis reveals that the overall cases of ascites due to cirrhosis in the 7MM was reported as ~244K in 2022.
- Assessments as per DelveInsight’s analysts showed that there were 27K cases of Grade I ascites due to cirrhosis in the United States in 2022 which was nearly 22% of all grade ascites cases.
- Prominent companies working in the domain of ascites, including Ocelot Bio, Inc., PharmaIN, Grifols Therapeutics LLC, and others, are actively working on innovative drugs for Ascites. These novel ascites therapies are anticipated to enter the ascites market in the forecast period and are expected to change the market.
- Some of the key therapies for ascites treatment include OCE-205, PHIN-214 Subcutaneous injection, Albutein 20% Injectable Solution, and others.
Discover which therapies are expected to grab the ascites market share @ Ascites Market Size Report
Ascites Overview
Ascites is characterized by an abnormal accumulation of fluid within the peritoneal cavity, leading to the collection of fluid in the abdominal spaces. When ascites becomes severe, it can cause discomfort and hinder the patient’s ability to move comfortably. Additionally, it has the potential to pave the way for abdominal infections and may result in the movement of fluid into the chest, enveloping the lungs. This condition poses challenges to everyday activities such as eating, drinking, and mobility, and it can also impede normal breathing.
Ascites Epidemiology Segmentation
- Number of Ascites Cases due to Cirrhosis
- Number of Ascites Cases by Malignancies
- Severity-specific Cases of Ascites due to Cirrhosis
Download the report to understand which factors are driving ascites epidemiology trends @ Ascites Epidemiological Insights
Ascites Treatment Market
The management of ascites resulting from cirrhosis involves various approaches, including the use of diuretics, paracentesis, the placement of a transjugular intrahepatic portosystemic shunt (TIPS), and addressing complications such as spontaneous bacterial peritonitis (SBP). For mild and moderate cirrhotic ascites, treatment encompasses dietary sodium restriction, addressing the underlying condition, fluid restriction, diuretic use, and therapeutic paracentesis. In cases of refractory ascites associated with liver cirrhosis, the strategies involve optimizing medical care, performing serial large volume paracenteses, considering TIPS, peritoneovenous shunt, and exploring the option of liver transplantation.
Learn more about the FDA-approved drugs for ascites @ Drugs for Ascites Treatment
Key Ascites Therapies and Companies
The mid-stage developments of the ascites pipeline feature promising pharmaceuticals that are poised for approval shortly. Key contributors such as Ocelot Bio, Inc., along with other notable entities, can bring about a substantial positive change in the size of the ascites market.
Ocelot Bio, Inc. is in the process of developing OCE-205, a therapy under investigation aimed at revolutionizing the treatment of end-stage liver disease (ESLD). The company is also exploring the potential of OCE-205 for addressing ascites, a complication arising from ESLD-induced portal hypertension that results in the accumulation of fluid in the peritoneal cavity. Ascites significantly reduce the quality of life and serve as an indicator of a more challenging prognosis for individuals grappling with ESLD. Presently, the company is engaged in a Phase II multi-center, randomized, placebo-controlled, double-blind, adaptive dose-ranging study to evaluate the safety and effectiveness of intravenous OCE-205 in adults diagnosed with cirrhosis with ascites, particularly those who have developed hepatorenal syndrome-acute kidney injury (HRS-AKI).
To know more about ascites clinical trials, visit @ Ascites Drugs
Ascites Market Dynamics
The ascites market dynamics are anticipated to change in the coming years. The rise in the patient population with underlying conditions such as liver cirrhosis, alcoholism, kidney or heart failure, malignancy, etc., may contribute to an increase in the incidence of ascites. The growing healthcare activities and campaigns emphasizing the importance of addressing ascites are bolstering the market. The Serum-Ascites Albumin Gradient plays a crucial role in accurately differentiating ascites fluid, achieving a 90% accuracy rate, and successfully identifying the underlying conditions.
Scope of the Ascites Market Report
- Ascites Therapeutic Assessment: Ascites current marketed and emerging therapies
- Ascites Market Dynamics: Attribute Analysis of Emerging Ascites Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Ascites Market Access and Reimbursement
Discover more about ascites drugs in development @ Ascites Clinical Trials
Table of Contents
1. Key Insights
2. Executive Summary of Ascites
3. Competitive Intelligence Analysis for Ascites
4. Ascites: Market Overview at a Glance
5. Ascites: Disease Background and Overview
6. Patient Journey
7. Ascites Epidemiology and Patient Population
8. Ascites Treatment Algorithm, Current Treatment, and Medical Practices
9. Ascites Unmet Needs
10. Key Endpoints of Ascites Treatment
11. Ascites Marketed Products
12. Ascites Emerging Therapies
13. Ascites: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Ascites Market Outlook
16. Ascites Market Access and Reimbursement Overview
17. Ascites KOL Views
18. Ascites Market Drivers
19. Ascites Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
